BIVI BioVie Inc. Class A

BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.

$16.90
As of 06/23/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/05/2014
Outstanding shares:  13,972,016
Average volume:  47,352
Market cap:   $237,384,552
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   20.73
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy